Immune Thrombocytopenia (ITP): Epidemiology Forecasting Intelligence
Report ID: 228329 | Mar 2019 | No. of Pages: 70
|
Publisher's "Immune Thrombocytopenia (ITP)-Epidemiology Forecasting Intelligence" report provides a comprehensive analysis of the Immune Thrombocytopenia (ITP) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.
Our epidemiology services include:
- Incidence and prevalence
- Diagnosis rate, treatment rate and mortality patterns
- Epidemiology-based forecasting and disease trends
- Size of different patient segments in a disease area
- Population based: disease occurrence, co-morbidities and treatment patterns
- Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
- Patient treatment journey
- Treatment algorithm and guidelines
- Assesses the disease risk and burden
- Highlights the unmet needs
- Market driver and barrier
- Growth opportunities and market trend analysis
Methodology
- This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
- To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
- All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Our epidemiology services include:
- Incidence and prevalence
- Diagnosis rate, treatment rate and mortality patterns
- Epidemiology-based forecasting and disease trends
- Size of different patient segments in a disease area
- Population based: disease occurrence, co-morbidities and treatment patterns
- Geographic - Regional - Ethnic differences
Along with the epidemiological data, the report also includes:
- Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
- Patient treatment journey
- Treatment algorithm and guidelines
- Assesses the disease risk and burden
- Highlights the unmet needs
- Market driver and barrier
- Growth opportunities and market trend analysis
Methodology
- This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
- To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
- All of the sources used to generate the data and analysis have been identified in the report.
Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
TABLE OF CONTENTS1. Report Introduction
2. Immune Thrombocytopenia (ITP) Epidemiology Overview at a Glance
3. Market Share Distribution of Immune Thrombocytopenia (ITP)
4. Disease Background and Overview: Immune Thrombocytopenia (ITP)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Immune Thrombocytopenia (ITP) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Immune Thrombocytopenia (ITP) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
7.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
7.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
7.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
7.6. Treated Cases of Immune Thrombocytopenia (ITP)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.1.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.1.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.1.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.1.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.2.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.2.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.2.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.2.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.3.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.3.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.3.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.3.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.4.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.4.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.4.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.4.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.5.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.5.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.5.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.5.6. Treated Cases of Immune Thrombocytopenia (ITP)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
9.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
9.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
9.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
9.6. Treated Cases of Immune Thrombocytopenia (ITP)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About Publisher
- Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM
Table 2: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in United States
Table 4: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Table 5: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Table 6: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in United States
Table 7: Treated Cases of the Immune Thrombocytopenia (ITP) in United States
Table 8: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 9: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Table 10: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Table 11: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 12: Treated Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 13: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in France
Table 14: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Table 15: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Table 16: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in France
Table 17: Treated Cases of the Immune Thrombocytopenia (ITP) in France
Table 18: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 19: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Table 20: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Table 21: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 22: Treated Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 23: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 24: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Table 25: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Table 26: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 27: Treated Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 28: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in UK
Table 29: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Table 30: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Table 31: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in UK
Table 32: Treated Cases of the Immune Thrombocytopenia (ITP) in UK
Table 33: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Japan
Table 34: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Table 35: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Table 36: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Japan
Table 37: Treated Cases of the Immune Thrombocytopenia (ITP) in Japan
- Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 4: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Figure 5: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Figure 6: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 7: Treated Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 8: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 9: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Figure 10: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Figure 11: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 12: Treated Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 13: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in France
Figure 14: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Figure 15: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Figure 16: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in France
Figure 17: Treated Cases of the Immune Thrombocytopenia (ITP) in United France
Figure 18: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 19: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Figure 20: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Figure 21: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 22: Treated Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 23: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 24: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Figure 25: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Figure 26: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 27: Treated Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 28: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 29: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Figure 30: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Figure 31: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 32: Treated Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 33: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Japan
Figure 34: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Figure 35: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Figure 36: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Japan
Figure 37: Treated Cases of the Immune Thrombocytopenia (ITP) in Japan
- Indication Specific
2. Immune Thrombocytopenia (ITP) Epidemiology Overview at a Glance
3. Market Share Distribution of Immune Thrombocytopenia (ITP)
4. Disease Background and Overview: Immune Thrombocytopenia (ITP)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Immune Thrombocytopenia (ITP) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Immune Thrombocytopenia (ITP) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
7.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
7.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
7.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
7.6. Treated Cases of Immune Thrombocytopenia (ITP)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.1.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.1.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.1.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.1.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.2.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.2.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.2.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.2.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.3.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.3.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.3.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.3.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.4.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.4.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.4.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.4.6. Treated Cases of Immune Thrombocytopenia (ITP)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
8.5.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
8.5.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
8.5.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
8.5.6. Treated Cases of Immune Thrombocytopenia (ITP)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Immune Thrombocytopenia (ITP)
9.3. Sub-Type Specific cases of Immune Thrombocytopenia (ITP)-
9.4. Sex- Specific Cases of Immune Thrombocytopenia (ITP)-
9.5. Diagnosed Cases of Immune Thrombocytopenia (ITP)
9.6. Treated Cases of Immune Thrombocytopenia (ITP)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About Publisher
- Indication Specific
Note: Certain sections of the table of contents would vary according to the availability of information.
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM
Table 2: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in United States
Table 4: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Table 5: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Table 6: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in United States
Table 7: Treated Cases of the Immune Thrombocytopenia (ITP) in United States
Table 8: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 9: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Table 10: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Table 11: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 12: Treated Cases of the Immune Thrombocytopenia (ITP) in Germany
Table 13: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in France
Table 14: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Table 15: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Table 16: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in France
Table 17: Treated Cases of the Immune Thrombocytopenia (ITP) in France
Table 18: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 19: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Table 20: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Table 21: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 22: Treated Cases of the Immune Thrombocytopenia (ITP) in Italy
Table 23: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 24: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Table 25: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Table 26: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 27: Treated Cases of the Immune Thrombocytopenia (ITP) in Spain
Table 28: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in UK
Table 29: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Table 30: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Table 31: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in UK
Table 32: Treated Cases of the Immune Thrombocytopenia (ITP) in UK
Table 33: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Japan
Table 34: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Table 35: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Table 36: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Japan
Table 37: Treated Cases of the Immune Thrombocytopenia (ITP) in Japan
- Indication Specific
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 4: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Figure 5: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in United States-
Figure 6: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 7: Treated Cases of the Immune Thrombocytopenia (ITP) in United States
Figure 8: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 9: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Figure 10: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Germany-
Figure 11: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 12: Treated Cases of the Immune Thrombocytopenia (ITP) in Germany
Figure 13: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in France
Figure 14: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Figure 15: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in France-
Figure 16: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in France
Figure 17: Treated Cases of the Immune Thrombocytopenia (ITP) in United France
Figure 18: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 19: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Figure 20: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Italy-
Figure 21: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 22: Treated Cases of the Immune Thrombocytopenia (ITP) in Italy
Figure 23: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 24: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Figure 25: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Spain-
Figure 26: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 27: Treated Cases of the Immune Thrombocytopenia (ITP) in Spain
Figure 28: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 29: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Figure 30: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in UK-
Figure 31: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 32: Treated Cases of the Immune Thrombocytopenia (ITP) in UK
Figure 33: Prevalent/Incident Cases of the Immune Thrombocytopenia (ITP) in Japan
Figure 34: Sub-Type Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Figure 35: Sex- Specific Cases of the Immune Thrombocytopenia (ITP) in Japan-
Figure 36: Diagnosed Cases of the Immune Thrombocytopenia (ITP) in Japan
Figure 37: Treated Cases of the Immune Thrombocytopenia (ITP) in Japan
- Indication Specific
1. This report provides in depth analysis for changing competitive dynamics and keeps you ahead of competitors
2. It provides a forward looking perspective on different factors driving or restraining market growth
3. It provides a ten-year forecast assessed on the basis of how the market is expected to grow
4. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of various market segments
Connect With Us
+1-707-633-0404
sales@search4research.com
Related reports
|
|
ECG Management Systems Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Adult Day Care Services Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Virtual Microscopy Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Teledentistry Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |
|
|
Medical Second Opinion Market Growth Opportunities to 2030 - North America, Europe, Asia-Pacific, South America, Middle East and Africa
Publication Month: May 2024 | No. of Pages: 120
|
$4750Buy Now |